TY - JOUR
T1 - Evidence-based management of pregnant women with sickle cell disease in high-income countries
AU - Oteng-Ntim, Eugene
AU - Shangaris, Panicos
N1 - Publisher Copyright:
Copyright © 2022 by The American Society of Hematology.
PY - 2022/12/9
Y1 - 2022/12/9
N2 - Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2).
AB - Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2).
UR - http://www.scopus.com/inward/record.url?scp=85143917534&partnerID=8YFLogxK
U2 - 10.1182/hematology.2022000378
DO - 10.1182/hematology.2022000378
M3 - Article
C2 - 36485166
SN - 1520-4383
VL - 2022
SP - 408
EP - 413
JO - Hematology. American Society of Hematology. Education Program
JF - Hematology. American Society of Hematology. Education Program
IS - 1
ER -